Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus TECHNETIUM TC 99M PENTETATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus TECHNETIUM TC 99M PENTETATE KIT.
SODIUM IODIDE I 131 vs TECHNETIUM TC-99M PENTETATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
Technetium-99m pentetate is a radiopharmaceutical that, after intravenous administration, distributes in the extracellular space and is excreted by glomerular filtration. It is used to assess renal function and for imaging. The Tc-99m label emits gamma rays for detection.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
Intravenous administration of 3-10 mCi (111-370 MBq) for renal imaging in adults. For cerebrospinal fluid (CSF) imaging, 0.5-2 mCi (18.5-74 MBq) intrathecally.
None Documented
None Documented
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
1.9 hours (terminal elimination half-life). Clinically, effective half-life is ~6 hours due to physical decay of Tc-99m (t½ 6.02 h) combined with biological clearance.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Primarily renal; 90-95% of injected dose excreted unchanged in urine within 24 hours via glomerular filtration. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical